Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Nuclear osteopontin-c is a prognostic breast cancer marker*

Posted by on in 2015
  • Font size: Larger Smaller
  • Hits: 1074
  • Print

Zduniak K1Ziolkowski P1Ahlin C2Agrawal A3Agrawal S3Blomqvist C4Fjällskog ML4Weber GF5. 2015. Br J Cancer. 112(4):729-38. doi: 10.1038/bjc.2014.664. Epub 2015 Jan 27.

 

  • 1Department of Pathology, Wroclaw Medical University, 50-367 Wroclaw, Poland.
  • 2Department of Oncology, Örebro University Hospital, SE-70185 Örebro, Sweden.
  • 3Department of General and Oncological Surgery, Wroclaw Medical University, 50-367 Wroclaw, Poland.
  • 4Department of Radiology, Oncology and Radiation Sciences, Uppsala University, 751 05 Uppsala, Sweden.
  • 5College of Pharmacy, University of Cincinnati Academic Health Center, Cincinnati, OH 45267, USA.

Abstract

BACKGROUND:

Although Osteopontin has been known as a marker for cancer progression, the elevated production of this cytokine is not specific for cancer. We have identified the splice variant Osteopontin-c as being absent from healthy tissue but associated with about 75% of breast cancer cases. However, in previous studies of Osteopontin-c, follow-up information was not available.

METHODS:

Here we have analysed 671 patients, comprising a cohort of 291 paraffin blocks plus a population-based case-control study of 380 arrayed breast tumor tissues.

RESULTS:

We find that high staining intensity of nuclear Osteopontin-c is strongly associated with mortality in patients with early breast cancer. Cytosolic staining for exon 4, reflective of Osteopontin-a and -b also predicts poor outcome. By contrast, total Osteopontin does not correlate with prognosis. These diverse assessments of Osteopontin also do not correlate with each other, suggesting distinct expression patterns for the variant forms. Consistent with its role in tumor progression, not tumor initiation, Osteopontin-c is not correlated with proliferation markers (Ki-67, cyclin A, cyclin B, cyclin E and cyclin D), neither is it correlated with ER, PR or HER2.

CONCLUSIONS:

The addition of Osteopontin-c immunohistochemistry to standard pathology work-ups may have prognostic benefit in early breast cancer diagnosis.

*Note:
The chicken anti-human osteopontin used in this study is available from Gallus Immunotech in the Anti-Human Proteins section of our website.

Buy it here:

Last modified on